Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

NCT05837689 is registered in ClinicalTrials.gov with Xiaojun Xu as lead sponsor.

NCT NCT05837689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05837689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation
Lead sponsor
Xiaojun Xu
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2023
Completion date
April 30, 2023
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, pediatric